wegovy mash - Search News

Order byBest matchMost fresh

News

MASH, Novo and Wegovy

Fierce Pharma · 7h

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

Continue reading

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

Novo Wins MASH Approval for Wegovy

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Investor's Business Daily on MSN1h

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.

Wegovy Approved for Noncirrhotic MASH With Moderate, Advanced Liver Fibrosis

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

MedPage Today3h

Semaglutide Gets FDA Greenlight for MASH

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results